Literature DB >> 11505460

Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice.

M D Wareing1, J M Watson, M J Brooks, G A Tannock.   

Abstract

The immunogenicity of the Russian cold-adapted (ca) donor stains, A/Leningrad (Len)/134/17/57 and A/Leningrad/134/47/57, and the US strain A/Ann Arbor (AA)/6/60-ca, were compared in BALB/c mice with their respective wild-type parental viruses. Each ca donor strain was less immunogenic than its wild-type parent. The vaccinating dose, when administered twice, which prevented multiplication of a standard challenge of parental wild-type virus in 50% of mice (the 50% protective dose or PD(50)), was shown for A/Len/134/17/57-ca, A/Len/134/47/57-ca, and A/AA/6/60-ca to be 10(3.77), 10(4.32), and 10(4.70), respectively. These findings were extended by measuring the number of antibody secreting cells induced in the lungs and mediastinal lymph nodes of mice infected with the same ca donors using an ELISPOT assay. When each donor strain was administered twice at a dose of 100 PD(50) over a 3-week interval, the overall immunoglobulin isotype antibody secreting cell profiles were shown to be similar. However, A/Len/134/17/57-ca and A/Len/134/47/57-ca induced significantly higher total immunoglobulin responses in the lungs than A/AA/6/60-ca (P < 0.05). A/Len/134/17/57-ca also induced a significantly greater IgA response in the lungs than A/AA/6/60-ca (P < 0.05). These results suggest that A/Len/134/17/57-ca is a superior immunogen to A/Len/134/47/57-ca which in turn is more immunogenic than A/AA/6/60-ca. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505460

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.

Authors:  Yasuko Hatta; Masato Hatta; Pamuk Bilsel; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.

Authors:  Tatiana Kotomina; Daniil Korenkov; Victoria Matyushenko; Polina Prokopenko; Larisa Rudenko; Irina Isakova-Sivak
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

3.  Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Authors:  Irina Isakova-Sivak; Li-Mei Chen; Melissa Bourgeois; Yumiko Matsuoka; J Theo M Voeten; Jacco G M Heldens; Han van den Bosch; Alexander Klimov; Larisa Rudenko; Nancy J Cox; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

4.  Construction and identification of influenza plasmid pool imparting high yields to candidate vaccine viruses in Vero cell at low temperature.

Authors:  Ze Liu; Xingliang Geng; Zhaohai Cui; Weidong Li; Xia Ou; Guoyang Liao
Journal:  J Cell Mol Med       Date:  2020-09-09       Impact factor: 5.310

5.  Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets.

Authors:  Jasmina M Luczo; Tatiana Bousse; Scott K Johnson; Cheryl A Jones; Nicholas Pearce; Carlie A Neiswanger; Min-Xuan Wang; Erin A Miller; Nikolai Petrovsky; David E Wentworth; Victor Bronshtein; Mark Papania; Stephen M Tompkins
Journal:  NPJ Vaccines       Date:  2021-04-21       Impact factor: 7.344

6.  Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.

Authors:  Natalia A Ilyushina; Mine R Ikizler; Yoshihiro Kawaoka; Larisa G Rudenko; John J Treanor; Kanta Subbarao; Peter F Wright
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

7.  Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Authors:  Irina Isakova-Sivak; Jørgen de Jonge; Tatiana Smolonogina; Andrey Rekstin; Geert van Amerongen; Harry van Dijken; Justin Mouthaan; Paul Roholl; Victoria Kuznetsova; Elena Doroshenko; Vadim Tsvetnitsky; Larisa Rudenko
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.